Background: The aim of this study was to elucidate the clinical outcomes of patients with STSs who received additional excisions after unplanned excisions (UE) using data from the Bone and Soft Tissue Tumor Registry in Japan. Methods: We examined 197 patients with STSs who received an additional excision after a UE. Data from 2006 to 2013 were obtained from the BSTT Registry. There were 112 men and 85 women, with a mean age of 54 years. The mean primary tumor size was 4.7 cm. Tumor depth was classified as superficial (n = 132) or deep (n = 65). Results: Residual tumor cells were observed in 115 of 197 (58%) specimens at additional excision. Wide margins were achieved in 190 patients, whereas marginal or intra-lesional margins were made in seven patients. One hundred and five patients (53%) required plastic reconstructions. The 5-year disease-specific survival rate was 97.4%. Local recurrence occurred in 15 patients, and the 5-year local recurrence-free rate was 91%. Residual tumor tissue in re-excision specimens was an independent prognostic factor for local control (P = 0.04). The 5-year local recurrence-free rate was significantly worse in patients with residual tumors than in those without residual tumors. Conclusions: We suggest that UEs should be avoided because they require additional excisions and, in many cases, subsequent soft tissue reconstruction. Additional excisions that are sufficiently extensive may improve local control, although patients with residual tumor tissue in reexcision specimens should be carefully followed up.
Introduction
Owing to their rarity, soft tissue sarcomas (STSs) are often resected without a work-up, which impedes accurate and timely diagnosis (1) . In such unplanned excisions (UEs), there is no intent to achieve tumor-free margins and the direction of the skin incision is not considered. This significantly increases the risk of local recurrence, and residual tumor tissue is indeed present in 24-91% of re-excision (additional excision) specimens (1) (2) (3) (4) . To reduce the possibility of recurrence, surgical oncologists perform additional excisions after UEs. Additional excisions require more extensive surgical margins than do conventional wide-margin excisions because reactive changes after UEs and inappropriate skin incisions can cause tumor cell contamination of non-tumor regions (2, 5) .
The Bone and Soft Tissue Tumor (BSTT) Registry is a nationwide organ-specific cancer registry for bone and soft tissue tumors in Japan. It was made available to physicians in 2014 after approval by the Musculoskeletal Tumor Committee of the Japan Orthopaedic Association (JOA) (6) . The aim of this study was to elucidate the clinical outcomes of patients with STSs who received additional excisions after UEs using data from the BSTT Registry.
Patients and methods

Data source
Launched in 1950s, the BSTT registry is organized and funded by the JOA and promoted by the National Cancer Center. It consists of detailed data collected annually from patients at the participating hospitals in a clinician-oriented manner. The data include basic patient characteristics, tumor characteristics, surgical and nonsurgical procedures, and complications. Information on prognosis 2, 5 and 10 years after the initial registration is also collected. This study was approved by the institutional Review Board of the JOA and Mie University Hospital. Informed consent was waived by IRB of JOA and Mie University Hospital because of the nature of present study.
Data extraction
We examined patients with STSs who received an additional excision after a UE. Data from 2006 to 2013 were obtained from the BSTT Registry and included patient age and sex; tumor size, location, depth and grade; histologic diagnosis; date of diagnosis; treatment details; postoperative complications and prognosis at the last follow-up. Patients with local recurrence and metastasis at the time of registration in the BSTT Registry were excluded. The minimum follow-up period was 2 years after the additional excision.
Statistical analyses
Statistical associations between clinicopathological variables were evaluated by using the Mann-Whitney U and Kruskal-Wallis tests for quantitative data and the chi-square test for qualitative data. Survival time was measured from the date of diagnosis of the primary tumor to the date of sarcoma-related death or last follow-up. Local recurrence time was measured from the date of diagnosis of the primary tumor to the date of local recurrence. Survival curves were generated by using the Kaplan-Meier method and compared by using the log-rank test. Univariate and multivariate analyses were performed by using Cox proportional hazards regression models. All statistical analyses were conducted by using StatView for Windows, version 5.0 (SAS Institute Inc., Cary, NC, USA). P values < 0.05 were considered significant.
Results
Clinicopathological characteristics
Our study consisted of 197 patients with STSs who received an additional excision and followed-up more than 2 years after additional excision except for the patients who developed additional oncological events within 2 years. There were 112 men and 85 women, with a mean age of 54 (range, 4-89) years ( Table 1) . The mean and median follow-up duration was 48 and 41 (range, 7-115) months, respectively. Primary tumor sites included the thigh (55 patients), lower leg (25 patients), forearm (22 patients), back (20 patients), inguinal region (13 patients), knee (9 patients), chest wall (8 patients), upper arm (7 patients), buttocks (6 patients), shoulder (5 patients) and others (27 patients). The tumors were histologically classified as undifferentiated pleomorphic sarcomas/ malignant fibrous histiocytomas (UPS/MFH) (n = 51), liposarcomas (n = 37), myxofibrosarcomas (MFS) (n = 26), leiomyosarcomas (n = 24), synovial sarcomas (n = 12), malignant peripheral nerve sheath tumors (n = 11), fibrosarcomas (n = 11) or other (n = 25). The mean primary tumor size at diagnosis was 4.7 (range, 0.5-20) cm. Tumor depth was classified as superficial (n = 132) or deep (n = 65). Residual tumor cells were observed in 115 of 197 (58%) specimens at additional excision. Microscopic residual tumor cells were observed in 83 patients, whereas macroscopic residual tumors were observed in 32 patients. Wide margins were achieved in 109 of 115 patients who had residual tumor cells, whereas marginal or intra-lesional margins were made in six patients. Thirty-eight patients received adjuvant chemotherapy (preoperative, 3; postoperative, 28; both, 7), and 17 patients received adjuvant radiotherapy (preoperative, 2; postoperative, 15). One hundred and five patients (53%) required plastic reconstructions including skin grafts (n = 50), pedicled myocutaneous flaps (n = 41), free myocutaneous flaps (n = 19) and other procedures (n = 6). Reconstructions were more often performed in the distal parts of the extremities (e.g., the forearm and lower leg) than in the proximal parts of the extremities and trunk (P = 0.03) ( Table 2 ). Fourteen patients required additional surgery because of wound complications, such as delayed healing (n = 9) or infection (n = 3). Clinicopathological differences between superficial and deep tumors
Tumors arising in the deep layer (mean, 5.5 cm) were larger than those arising in the superficial layer (mean, 4.4 cm) (P = 0.02). Furthermore, re-excision specimens from deep tumors more often contained residual tumor tissue than did those from superficial tumors (P = 0.03). Age, sex, tumor grade, tumor site, surgical margin status, and reconstruction were not associated with tumor depth (Table 3) . Histologically, residual tumors were observed in more than 70% of patients with MFS and UPS/MFH (Table 4) .
Predictable factor for local control
At the last follow-up, six patients had died of the disease. . In a univariate analysis using a Cox proportional hazards model, local control correlated with residual tumor tissue in re-excision specimens, and tumor size ( Table 5 ). The 5-year local recurrence-free survival was significantly worse in patients with macroscopic residual tumors (80.7%, 95% CI: 66.8-94.6%) than in those without residual tumors (97.3%, 95% CI: 93.6-100%) (P = 0.001) (Fig. 1 ). There was marginal difference for local control between the patients with microscopic residual tumor cells and no residual tumors (P = 0.08). The 5-year local recurrence-free survival in patients with microscopic residual tumor cells was 88.3% (95% CI: 79.1-97.6%) (Fig. 1) . In 141 patients who had information of tumor size, 38 patients had > 5 cm tumors and they had significantly poorer local control (75.8% at 5 years, 95%CI: 60.4-91.2%) compared with those with < 5 cm tumors (95.6% at 5 years, 95% CI: 91.4-99.9%). Of 115 patients who had residual tumor cells, there was a marginal difference of local recurrence-free survival between patients with wide surgical margin at additional excision and those with marginal and intra-lesional margin (P = 0.06). Multivariate analysis was not performed because tumor size in 56 patients was not recorded by the hospitals and remaining predictable factor was residual tumor tissue in re-excision specimens alone.
Discussion
Using the BSTT registry, the present study analyzed 197 patients with STSs who received additional excision and followed-up more than 2 years after additional excision. Our analysis identified residual tumor tissue in re-excision specimens as an independent prognostic factor for local control. Furthermore, tumor size may also be an independent prognostic factor for local control, although tumor size was missing in 28% of patients because of lack of information at previous hospital. In our study, as in most studies of STSs treated via UE and additional excision, residual tumors were observed in~50% of the patients; however, the range (24-91%) is wide (1,2,4,5). Interestingly, the rate of residual tumors was different in the type of histological diagnosis. The infiltrative growth pattern has established for both UPS/MFH and MFS (7, 8) . Our findings may reflect the infiltrative characteristic of those tumors. Residual tumor tissue can be a confounding factor that is affected by other factors; hence, its presence should be interpreted with caution. Although residual tumor-positive status is thought to reflect inattention to achievement of tumor-free margins, it may partially reflect tumor invasiveness (9, 10) . In present study, local recurrence-free survival in patients with macroscopic residual tumors was poorer than that in those without residual tumors. Furthermore, there was marginal difference for local control between the patients with microscopic residual tumor cells and no residual tumors (P = 0.08). Therefore, patients with residual tumor tissue in re-excision specimens obtained require careful follow-up.
Soft tissue reconstruction was often required after a UE. This suggests that the UEs performed in the referring hospitals caused widespread tumor cell contamination, which created the need for a wider re-excision area to obtain a negative surgical margin (11) (12) (13) . In the present study, 53% of the patients received skin grafts and/or myocutaneous flaps despite wide surgical margins in 96% of these patients. Reconstruction was necessary in patients with STSs in the distal parts of the extremities, perhaps because of insufficient soft tissue for wound closure after additional excision.
What remains controversial is the impact of UEs on survival outcome (9) (10) (11) (12) (13) (14) (15) . In the present study, survival was quite good (5-year DSS rate: 97.4%), perhaps because the primary tumors were small (mean, 4.7 cm) and more often superficial than deep (9, 15) . Even the deep tumors were relatively small (mean: 5.5 cm). Furthermore, 51 of 197 patients had low grade sarcoma in present study. Bianchi et al. reported that 5-year DSS was 77% in 452 patients with highgrade soft tissue sarcoma who received unplanned excision (16) . On the other hand, Lewis et al. reported that 5-year DSS was 88% in 1092 patients with soft tissue sarcoma who received unplanned excision. Three hundred and seventy four of 1092 patients had low grade sarcoma (17) . However, we should consider the selection bias and limitation of BSTT Registry system when we interpret those results. First, we excluded the patients without additional excision after unplanned excision. For example, some patients may receive adjuvant radiotherapy alone after unplanned excision. We cannot know the detail of dose of radiation or chemotherapy in BSTT Registry system. Second, BSTT Registry system does not include all patients who received additional excision after unplanned excision in Japan, although BSTT Registry is biggest system. Interestingly, the incidence of residual tumor tissue was significantly greater in patients with deep versus superficial tumors, even though tumor depth did not significantly affect the local control rate. However, 45% of the patients with deep tumors required soft tissue reconstruction. These results indicate that local recurrence can be avoided if deep STSs are resected with wide margins, although reconstruction after additional excision may be necessary.
Tumor size was prognostic factor for local control in patients with conventional tumor resection. Interestingly, tumor size was also an independent factor for local control in patients with UEs, even if the primary tumors were small in all patients. In 141 patients who had information of tumor size, 27% of patients had >5 cm tumors and they had significantly poorer local control, compared with those with <5 cm tumors.
Our study had some limitations. First, the study design was retrospective. Second, it did not control for several clinical parameters that may have affected outcome. For example, tumors in the BSTT registry are categorized as either low grade or high grade; hence, we could not divide high-grade sarcomas into Grades 2 and 3 according to the criteria of the French Federation of Cancer Centers Sarcoma Group. Functional outcome was also not evaluated because physicians do not have to enter this information into the registry. Despite these limitations, the present study is valuable because it analyzes data from a large organ-specific cancer registry (the BSTT registry); therefore, it may be largest study of clinical outcomes in patients with STSs who received UEs and subsequent additional excisions in Japan.
In conclusion, we suggest that UEs should be avoided because they require additional excisions and, in many cases, subsequent soft tissue reconstruction. Soft tissue tumors should be treated according to clinical guideline in soft tissue tumors at each country (18) . Additional excisions that are sufficiently extensive may improve local control, although patients with residual tumor tissue in re-excision specimens and/or bigger tumors should be carefully followed-up.
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